Please select the option that best describes you:
How would you sequence 177LU-PSMA-617 with current therapies for men with mCRPC?
Answer from: Medical Oncologist at Academic Institution
I would like to congratulate the VISION study investigators and Dr. @Michael J. Morris for the outstanding presentation and good news. The study was designed to use a hybrid control (best "standard of care"-SOC) and as such, it met its endpoints (OS, rPFS, etc). Secondary endpoints also significantl...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
We discuss these data and where this agent fits into the mCRPC landscape on a recent Uromigos podcast: https://anchor.fm/the-uromigos/episodes/Episode-113-Radionucleotides-in-prostate-cancer-e130uuq.
Comments
Medical Oncologist at Loyola University Chicago Stritch School of Medicine
Thanks for highlighting, really enjoyed the discus...
Thanks for highlighting, really enjoyed the discus...